Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Ranbaxy Discloses Interest In Shimal Research

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories disclosed in an annual report it had acquired a large part of Shimal Research Laboratories, a clinical-trial company, as long ago as February. Ranbaxy's annual report said the firm bought Oscar Investment's Shimal, which in turn owns Fortis Clinical Research. A Ranbaxy spokesperson would not respond to reports of the acquisition. An industry analyst suggested Ranbaxy should have made the disclosure in a more-timely manner. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts